Healthcare -
Biotechnology - NASDAQ - US
$ 0.405
20.8 %
$ 25.1 M
Market Cap
-0.55
P/E
1. INTRINSIC VALUE
Balance Sheet
Cognition Therapeutics, Inc.
| Current Assets | 29.6 M |
| Cash & Short-Term Investments | 25 M |
| Receivables | 2.69 M |
| Other Current Assets | 1.86 M |
| Non-Current Assets | 679 K |
| Long-Term Investments | 0 |
| PP&E | 679 K |
| Other Non-Current Assets | 0 |
| Current Liabilities | 11.1 M |
| Accounts Payable | 1.98 M |
| Short-Term Debt | 386 K |
| Other Current Liabilities | 8.77 M |
| Non-Current Liabilities | 342 K |
| Long-Term Debt | 684 K |
| Other Non-Current Liabilities | -342 K |
EFFICIENCY
Earnings Waterfall
Cognition Therapeutics, Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 54 M |
| Operating Income | -54 M |
| Other Expenses | -20 M |
| Net Income | -34 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Cognition Therapeutics, Inc.
| Net Income | -34 M |
| Depreciation & Amortization | 266 K |
| Capital Expenditures | -4 K |
| Stock-Based Compensation | 3.75 M |
| Change in Working Capital | 1.29 M |
| Others | 1.48 M |
| Free Cash Flow | -28.5 M |
Wall Street Analysts Price Targets
Cognition Therapeutics, Inc.
CGTX has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
CGTX does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Cognition Therapeutics, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
30 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer's Disease Surpasses 50% Enrollment Target
PURCHASE, N.Y., July 01, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced that the Phase 2 ‘START' Study surpasses 50% enrollment. The START Study is being conducted with partners at the Alzheimer's Clinical Trials Consortium (ACTC), with $81 million in grant support from the National Institute of Aging (NIA) at the National Institutes of Health.
globenewswire.com
- 5 days ago
Cognition Therapeutics Provides Regulatory Update on Zervimesine (CT1812) in Alzheimer's Disease and Dementia with Lewy Bodies (DLB)
- End-of-Phase 2 Meeting with FDA for Mild-to-Moderate Alzheimer's Disease Scheduled - - Applications for IND and Breakthrough Status Filed for Dementia with Lewy Bodies - PURCHASE, N.Y., June 25, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced that the company will conduct an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) on July 9, 2025.
globenewswire.com
- 1 week ago
Philanthropic Donor Funds Cognition Therapeutics' Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
Dr. James Galvin of the University of Miami to Serve as Lead Investigator First Site Initiated: Banner Sun Health Research Institute PURCHASE, N.Y., June 03, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced today it has received an anonymous philanthropic donation to substantially fund an expanded access program (EAP) for people with dementia with Lewy bodies (DLB).
globenewswire.com
- 1 month ago
Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Studying the Patient/Caregiver Lived Experience in Dementia with Lewy Bodies
PURCHASE, N.Y., May 28, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, has released its tenth Conversations video podcast episode: “Studying the Patient/Caregiver Lived Experience in Dementia with Lewy Bodies.”
globenewswire.com
- 1 month ago
Cognition Therapeutics Presented Data at Association for Research in Vision and Ophthalmology Showing Impact on Retinal Cell Health
PURCHASE, N.Y., May 09, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, reported preclinical data this week at the Association for Research in Vision and Ophthalmology (ARVO) showing the potential for zervimesine (CT1812) to protect retinal pigment epithelial (RPE) cells from damage in dry age-related macular degeneration (dry AMD).
globenewswire.com
- 1 month ago
Cognition Therapeutics Reports Financial Results for the First Quarter 2025 and Provides Business Update
- End-of-Phase 2 meeting with FDA requested for Alzheimer's disease - - Phase 2 results in dementia with Lewy bodies accepted for oral presentation at AAIC - - Two posters at ARVO describe zervimesine's role supporting retinal cell health - PURCHASE, N.Y., May 07, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, today reported financial results for the first quarter ended March 31, 2025, and provided a business update.
globenewswire.com
- 1 month ago
Cognition Therapeutics Presents Results at AD/PD 2025 Showing Impact of Zervimesine (CT1812) on Alzheimer's Disease Processes
Presentation Shows Pronounced Reduction in Key Plasma Biomarkers Among Prespecified Study Population Presentation Shows Pronounced Reduction in Key Plasma Biomarkers Among Prespecified Study Population
globenewswire.com
- 3 months ago
Cognition Therapeutics to Report Biomarker Results from Phase 2 SHINE Study in Mild-to-Moderate Alzheimer's Disease in Podium Presentation at AD/PD 2025
Additional Analyses to be Presented at AD/PD Include Correlation of CSF Biomarkers with Cognitive Outcomes, and Pharmacodynamic Biomarkers of Target Engagement Additional Analyses to be Presented at AD/PD Include Correlation of CSF Biomarkers with Cognitive Outcomes, and Pharmacodynamic Biomarkers of Target Engagement
globenewswire.com
- 3 months ago
Cognition Therapeutics, Inc (CGTX) Q4 2024 Earnings Call Transcript
Cognition Therapeutics, Inc (NASDAQ:CGTX ) Q4 2024 Results Conference Call March 20, 2025 8:00 AM ET Company Participants Mike Moyer - LifeSci Advisors Lisa Ricciardi - Chief Executive Officer John Doyle - Chief Financial Officer Anthony Caggiano - Chief Medical Officer, Head of R&D Conference Call Participants Mayank Mamtani - B. Riley Securities Daniil Gataulin - Chardan Operator Greetings, and welcome to the Cognition Therapeutics Fourth Quarter and Full Year 2024 Earnings Call.
seekingalpha.com
- 3 months ago
Cognition Therapeutics Reports Year End 2024 Financial Results and Provides Business Update
Positive Results with Zervimesine (CT1812) in Phase 2 SHIMMER Dementia with Lewy Bodies (DLB) Phase 2 SHINE Data Show Dramatic Slowing of Cognitive Decline with Zervimesine in a Key Pre-specified Alzheimer's Disease Subgroup 2025 Objective: Advance Zervimesine into Late-stage Trials for DLB and Alzheimer's Disease Management will Review Results at 8:00 a.m. ET on Live Webcast and Conference Call PURCHASE, N.Y.
globenewswire.com
- 3 months ago
Cognition Therapeutics to Report Fourth Quarter and Full Year 2024 Results
PURCHASE, N.Y., March 13, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), plans to release financial results for the fourth quarter and full year ended December 31, 2024, on Thursday, March 20, 2025, before the market open.
globenewswire.com
- 3 months ago
Cognition Therapeutics Granted Extension to Meet Nasdaq Minimum Bid Price Requirement for Continued Exchange Listing
PURCHASE N.Y., March 12, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), was notified by the Nasdaq Stock Market LLC (“Nasdaq”) on September 12, 2024 that the bid price of its common stock had closed at less than $1.00 per share over the previous 30 consecutive business days. As a result, Cognition was given 180 calendar days to regain compliance with the minimum bid price requirement, by achieving a closing bid price of at least $1.00 per share for 10 consecutive business days. The period to regain compliance with the minimum bid price requirement closed on March 11, 2025.
globenewswire.com
- 3 months ago
8. Profile
Summary
Cognition Therapeutics, Inc. CGTX
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 25.1 M
Dividend Yield
0.00%
Description
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.
Contact
2500 Westchester Avenue, Purchase, NY, 10577
https://www.cogrx.com
IPO
Date
Oct. 8, 2021
Employees
25
Officers
Ms. Anita Cornet
Head of Quality
Dr. Steven A. Weissman Ph.D.
Vice President & Head of CMC
Mr. John Brendan Doyle
Chief Financial Officer
Ms. Lisa Ricciardi
Chief Executive Officer, President & Director
Dr. Anthony O. Caggiano M.D., Ph.D.
Chief Medical Officer and Head of R&D
Mr. Bobby Horn
Corporate Controller